Want to see ACHV full AI Analyst Report?
ACHV Stock Chart & Stats
$8.17
$0.02(0.33%)
At close: 4:00 PM EDT
$8.17
$0.02(0.33%)
Day’s Range― - ―
52-Week Range$2.62 - $8.64
Previous CloseN/A
Volume586.58K
Average Volume (3M)1.55M
Market Cap
$667.84M
Enterprise Value$438.27M
Total Cash (Recent Filing)$187.30M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding102,902,490
10 Day Avg. Volume1,492,792
30 Day Avg. Volume1,546,897
Financial Highlights & Ratios
PEG Ratio-4.93
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.95K
Enterprise Value/Ebitda-3.88
Forecast
1Y Price Target
$13.83Price Target Upside69.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial LeadershipThe orderly CFO transition adds experienced financial leadership while preserving continuity in oversight. Halladay’s prior CFO background and defined retention arrangements may support capital planning, reporting discipline, and execution as Achieve funds development and prepares for potential commercialization.
Capital-Raising FlexibilityThe ATM program gives Achieve discretion over the timing and scale of equity issuance, creating a potential funding path for clinical development and commercialization. Access to capital can extend execution capacity and support advancement of the lead asset over the next several quarters.
Focused Development StrategyA focused lead program can concentrate the company’s limited resources, clinical expertise, and regulatory efforts on a defined medical need. Cytisinicline’s development for smoking cessation provides a coherent strategic direction rather than a broad, diffuse pipeline requiring multiple parallel investments.
Bears Say
No Commercial RevenueAchieve has not established a product-based revenue stream because its lead candidate remains investigational. This leaves operating performance dependent on clinical progress and future approval, making near-term financial outcomes uncertain and limiting the company’s ability to fund operations internally.
Persistent Cash BurnSustained negative operating and free cash flow shows that current activities consume capital rather than generate it. Continued clinical and corporate spending will therefore require additional funding, leaving Achieve exposed to financing conditions and potentially reducing resources available for development priorities.
Balance-Sheet StrainNegative equity materially weakens financial flexibility even though absolute debt is described as moderate. Combined with larger losses and ongoing cash needs, the capital structure increases reliance on external financing and raises the likelihood that future funding could dilute existing shareholders.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $2.62 and its highest was $8.64 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $667.84M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Aug 10, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.165 by -$0.635.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.2.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 102,902,490 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.165. Following the earnings report the stock price went up 0.301%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.83 (69.32% Upside)
$13.83 (69.32% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.91%
12-Months-Change
Fundamentals
Return on Equity
-892.07%
Trailing 12-Months
Asset Growth
223.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
ACHV Stock 12 Month Forecast
Average Price Target
$13.83
▲(69.32% Upside)
Technical Analysis
Vanda
―
Minerva Neurosciences
―
Anavex Life Sciences
―
AC Immune SA
―
Ovid Therapeutics
―
Ownership Overview
0.22%
Insiders
4.24% Mutual Funds
0.18% Other Institutional Investors
84.24% Public Companies and
Individual Investors